Log in

Medexus Pharmaceuticals Inc. (MDP.V) Stock Forecast, Price & News

+0.08 (+1.86 %)
(As of 10/23/2020 03:38 PM ET)
Today's Range
Now: C$4.37
50-Day Range
MA: C$4.05
52-Week Range
Now: C$4.37
Volume2,211 shs
Average Volume7,403 shs
Market CapitalizationC$63.16 million
P/E RatioN/A
Dividend YieldN/A
Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, which is indicated for the treatment of seasonal allergic rhinitis, perennial allergic rhinitis, and chronic spontaneous urticaria in patients 2 years of age and older. Its products portfolio also include Cuvposa, which is indicated for sialorrhea in patients aged 3-18 years with neurologic conditions, such as cerebral; Gliolan, an orally administered drug used for the visualization of various brain tumors; and Treosulfan, a conditioning agent used prior to stem cell transplantation. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Verdun, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 2.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.98 out of 5 stars

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic



Sales & Book Value

Annual SalesC$85.75 million
Cash FlowC$0.73 per share
Book ValueC$1.92 per share



Market CapC$63.16 million
Next Earnings Date12/4/2020 (Estimated)
+0.08 (+1.86 %)
(As of 10/23/2020 03:38 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MDP News and Ratings via Email

Sign-up to receive the latest news and ratings for MDP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Medexus Pharmaceuticals Inc. (MDP.V) (CVE:MDP) Frequently Asked Questions

How has Medexus Pharmaceuticals Inc. (MDP.V)'s stock been impacted by COVID-19 (Coronavirus)?

Medexus Pharmaceuticals Inc. (MDP.V)'s stock was trading at C$3.00 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MDP shares have increased by 45.7% and is now trading at C$4.37.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Medexus Pharmaceuticals Inc. (MDP.V)?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medexus Pharmaceuticals Inc. (MDP.V) in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Medexus Pharmaceuticals Inc. (MDP.V)

When is Medexus Pharmaceuticals Inc. (MDP.V)'s next earnings date?

Medexus Pharmaceuticals Inc. (MDP.V) is scheduled to release its next quarterly earnings announcement on Friday, December 4th 2020.
View our earnings forecast for Medexus Pharmaceuticals Inc. (MDP.V)

How were Medexus Pharmaceuticals Inc. (MDP.V)'s earnings last quarter?

Medexus Pharmaceuticals Inc. (MDP.V) (CVE:MDP) released its quarterly earnings data on Tuesday, August, 11th. The company reported ($0.31) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by $0.22. The firm earned $27.52 million during the quarter, compared to analysts' expectations of $27.20 million.
View Medexus Pharmaceuticals Inc. (MDP.V)'s earnings history

What price target have analysts set for MDP?

1 brokerages have issued twelve-month price objectives for Medexus Pharmaceuticals Inc. (MDP.V)'s shares. Their forecasts range from C$5.00 to C$5.00. On average, they expect Medexus Pharmaceuticals Inc. (MDP.V)'s stock price to reach C$5.00 in the next year. This suggests a possible upside of 14.4% from the stock's current price.
View analysts' price targets for Medexus Pharmaceuticals Inc. (MDP.V)

Who are some of Medexus Pharmaceuticals Inc. (MDP.V)'s key competitors?

What other stocks do shareholders of Medexus Pharmaceuticals Inc. (MDP.V) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medexus Pharmaceuticals Inc. (MDP.V) investors own include Gatekeeper Systems Inc. (GSI.V) (GSI), Enghouse Systems Limited (ENGH.TO) (ENGH), Antibe Therapeutics (ATE) and Ag Growth International (AFN).

Who are Medexus Pharmaceuticals Inc. (MDP.V)'s key executives?

Medexus Pharmaceuticals Inc. (MDP.V)'s management team includes the following people:
  • Mr. Kenneth d'Entremont, CEO & Director
  • Mr. Roland Boivin, Chief Financial Officer
  • Mr. Bill Poncy, Sr. VP of Commercial Operations - United States
  • Mr. Brian Peters, VP of Sales & Marketing - United States
  • Mr. Richard Labelle, VP of Sales & Marketing

What is Medexus Pharmaceuticals Inc. (MDP.V)'s stock symbol?

Medexus Pharmaceuticals Inc. (MDP.V) trades on the Canadian Venture Exchange (CVE) under the ticker symbol "MDP."

How do I buy shares of Medexus Pharmaceuticals Inc. (MDP.V)?

Shares of MDP and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is Medexus Pharmaceuticals Inc. (MDP.V)'s stock price today?

One share of MDP stock can currently be purchased for approximately C$4.37.

How big of a company is Medexus Pharmaceuticals Inc. (MDP.V)?

Medexus Pharmaceuticals Inc. (MDP.V) has a market capitalization of C$63.16 million and generates C$85.75 million in revenue each year.

What is Medexus Pharmaceuticals Inc. (MDP.V)'s official website?

The official website for Medexus Pharmaceuticals Inc. (MDP.V) is www.medexus.com.

How can I contact Medexus Pharmaceuticals Inc. (MDP.V)?

The company can be reached via phone at 514-762-2626.

This page was last updated on 10/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.